News

Wall Street looked set to recover after US banks posted impressive earnings, and inflation data was better than expected.

Stocks failed to continue Wednesday's rally as retail sales and fresh earnings from big banks took focus.

Palantir Technologies (PLTR) stock surged following the re-election of Donald Trump to The White House. Despite CEO Alex Karp’s opposition to Trump, the AI software company seems to have found support due to the close ties between Peter Thiel and soon-to-be vice president JD Vance. However, I’m bearish on the stock, simply because the valuation is very hard to sustain at this moment in time. While the company may experience a wealth of tailwinds when Trump is in office, we don’t know how large t

Wall Street paused, with stocks ending little changed. Strong bank earnings keep rolling in and Trump's Treasury pick fields Senate questions.

Richemont outstripped expectations with a 10 percent jump in revenue during the key holiday quarter, offering hope that luxury's slump might be coming to an end.

American Express (AXP) agreed to pay a total of about $230 million Thursday to settle allegations of past deceptive marketing practices associated with its wire products.

On Wednesday, ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC). NMIBC BCG Unresponsive Papillary Disease: ImmunityBio is preparing to submit a supplemental Biologics License Application (sBLA) in 2025 for its treatment targeting Bacillus Calmette-Guérin (BCG) unresponsive NMIBC in the papillary indication. As published in